Union Budget 2026 announced the setting up of Three New NIPERs under the BioPharma Shakti mission to boost research, advanced training, and skilled workforce development.
📊 Big News from Union Budget 2026!
The Government of India, led by Finance Minister Nirmala Sitharaman, has announced the setting up of three new NIPERs — National Institutes of Pharmaceutical Education and Research — as part of a major biopharma push under the BioPharma SHAKTI mission.
🔬 These additional NIPER institutions will expand India’s capacity in pharmaceutical education, research, innovation, and skilled workforce development, strengthening the biopharmaceutical sector and helping India become a global leader in biologics and biosimilars.
The Union Budget 2026–27, presented by the Hon’ble Union Minister for Finance and Corporate Affairs Smt. Nirmala Sitharaman in the Parliament today, has announced several key initiatives to strengthen India’s pharmaceutical and biopharma sector. The Minister emphasised scaling up of manufacturing in 7 strategic and frontier sectors including Pharmaceuticals to further accelerate and sustain economic growth.
Biopharma SHAKTI to Position India as a Global Biomanufacturing Hub
Underlining the importance of Biologic medicines at affordable costs to longevity and quality of life, the Finance Minister announced ‘Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology & Innovation)’ with a total outlay of ₹10,000 crore over the next five years. The programme is designed to develop India into a global biopharmaceutical manufacturing hub by building a strong and self-reliant ecosystem for the domestic production of biologics and biosimilars.
This initiative will catalyse investments in advanced biomanufacturing infrastructure, promote innovation and enhance India’s capabilities in high-value, next-generation therapies, thereby reducing import dependence and strengthening healthcare security.
🔥 Key Highlights
✔️ Three new NIPERs to be established nationwide.
✔️ Part of ₹10,000 crore BioPharma SHAKTI mission over five years.
✔️ 7 existing NIPERs to be upgraded for advanced research and industry skills.
✔️ Boosts India’s pharmaceutical education ecosystem & clinical research capabilities.
✨ Why This Matters
📍 Enhances NIPERs network for better pharma education & innovation.
📍 Builds a talent pipeline for high-value jobs in pharma and biotech R&D.
📍 Strengthens India’s position as a global biopharma hub.
| Existing NIPER | 7 |
| New NIPER | 3 |
| Total NIPERs | 10 |
Expansion of India’s Clinical Research Capacity
To further strengthen India’s position as a preferred destination for clinical research, under Biopharma SHAKTI, the Finance Minister said a network of over 1,000 accredited clinical trial sites across the country would be created.
This large-scale expansion will:
- Enhance the quality and credibility of clinical research in India
- Accelerate drug development timelines
- Improve access to cutting-edge therapies for Indian patients
- Generate significant opportunities for researchers, medical professionals and allied sectors
The Finance Minister also announced that the Central Drugs Standard Control Organisation would be strengthened to meet global standards and approval timeframes through a dedicated scientific review cadre and specialists.
Strengthening Pharmaceutical Education and Research: New NIPERs
Emphasising strengthening of pharmaceutical education and research in the country, the Finance Minister announced the establishment of three new National Institutes of Pharmaceutical Education and Research (NIPERs) along with the upgradation of the existing seven NIPERs. This step will enhance India’s capacity for advanced pharmaceutical education, high-end research and innovation. The expansion and modernisation of these premier institutes will help in developing a highly skilled workforce, promoting industry–academia collaboration, and supporting the growth of a globally competitive pharmaceutical and biopharmaceutical sector.
These measures collectively mark a significant step toward building a robust, innovation-driven, and globally competitive pharmaceutical and biopharmaceutical sector in India.
📌 Suggested Visuals
- Infographic: “3 New NIPERs Announced in Budget 2026”
- NIPER Mohali
- Data Points: 3 New NIPERs | ₹10,000 Cr | 7 Upgraded NIPERs | 1000 Clinical Sites
- CNCI Pharmacist Vacancy 2026- B. D. M. Pharma & Pharm D. Eligible Apply Now
- OSSSC Pharmacist Vacancy 2026- Upcoming Pharmacist Vacancy 1108 Post Vacant
- ICSIL Pharmacist Vacancy 2026 – D. & B. Pharma Freshers Eligible Apply Now
- Pharmacist Vacancy 2026 : D. Pharma & B. Pharma Freshers Candidate Eligible Apply Now
- Paramedical Vacancy 2026: 25,000+ Paramedical Vacancies Coming in 2026 | Central Govt Big Update